Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Antibe Therapeutics Inc. is set to present compelling safety and pharmacokinetic data for its non-opioid pain relief drug, otenaproxesul, at the upcoming ASRA Pain Medicine Meeting. The biotech firm is advancing its hydrogen sulfide-based platform, aiming to offer safer alternatives to traditional NSAIDs and opioids. Their lead drug, otenaproxesul, designed to reduce post-operative pain without the risk of abuse, will be highlighted by Chief Medical Officer Dr. Joseph Stauffer.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.